Phase III RECONNECT Trials FDA Approval Dataset The Phase III RECONNECT trials (RECONNECT-1 and RECONNECT-2) a pair of randomised, double-blind, placebo-controlled, multicentre studies enrolled approximately 1,247 premenopausal women with HSDD across North America and confirmed statistically significant improvements in the number of satisfying sexual events and reduction in distress from low sexual desire with bremelanotide 1.75 mg subcutaneous vs placebo
Advanced / Aggressive Approach (2 mL = 5 mg/mL) Reconstitute: Add 2.0 mL bacteriostatic water to the single 10 mg blend vial 5 mg/mL total peptide (5,000 mcg/mL)
Improving Cell Function: As it aids in energy production, it can help improve the overall function of various cells in our body
Step 1 Calculate concentration (mg/mL) Divide the total peptide in the vial (mg) by the volume of BAC water you added (mL)
WB results and green EGFP fluorescence in kidney sections confirmed successful rAAV9-PRMT1 transduction (Fig
Its popularity continues to rise as more people discover its effectiveness in tackling issues like hyperpigmentation, dullness, and the visible signs of aging
